These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38129255)

  • 1. Standards for the care of people with cystic fibrosis; establishing and maintaining health.
    Southern KW; Addy C; Bell SC; Bevan A; Borawska U; Brown C; Burgel PR; Button B; Castellani C; Chansard A; Chilvers MA; Davies G; Davies JC; De Boeck K; Declercq D; Doumit M; Drevinek P; Fajac I; Gartner S; Georgiopoulos AM; Gursli S; Gramegna A; Hansen CM; Hug MJ; Lammertyn E; Landau EEC; Langley R; Mayer-Hamblett N; Middleton A; Middleton PG; Mielus M; Morrison L; Munck A; Plant B; Ploeger M; Bertrand DP; Pressler T; Quon BS; Radtke T; Saynor ZL; Shufer I; Smyth AR; Smith C; van Koningsbruggen-Rietschel S
    J Cyst Fibros; 2024 Jan; 23(1):12-28. PubMed ID: 38129255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.
    Southern KW; Castellani C; Lammertyn E; Smyth A; VanDevanter D; van Koningsbruggen-Rietschel S; Barben J; Bevan A; Brokaar E; Collins S; Connett GJ; Daniels TWV; Davies J; Declercq D; Gartner S; Gramegna A; Hamilton N; Hauser J; Kashirskaya N; Kessler L; Lowdon J; Makukh H; Martin C; Morrison L; Nazareth D; Noordhoek J; O'Neill C; Owen E; Oxley H; Raraigh KS; Raynal C; Robinson K; Roehmel J; Schwarz C; Sermet I; Shteinberg M; Sinha I; Takawira C; van Mourik P; Verkleij M; Waller MD; Duff A
    J Cyst Fibros; 2023 Jan; 22(1):17-30. PubMed ID: 36916675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria.
    Castellani C; De Boeck K; De Wachter E; Sermet-Gaudelus I; Simmonds NJ; Southern KW;
    J Cyst Fibros; 2022 Nov; 21(6):908-921. PubMed ID: 36220763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
    Derichs N
    Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K; Clancy JP
    Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues.
    Burgel PR; Southern KW; Addy C; Battezzati A; Berry C; Bouchara JP; Brokaar E; Brown W; Azevedo P; Durieu I; Ekkelenkamp M; Finlayson F; Forton J; Gardecki J; Hodkova P; Hong G; Lowdon J; Madge S; Martin C; McKone E; Munck A; Ooi CY; Perrem L; Piper A; Prayle A; Ratjen F; Rosenfeld M; Sanders DB; Schwarz C; Taccetti G; Wainwright C; West NE; Wilschanski M; Bevan A; Castellani C; Drevinek P; Gartner S; Gramegna A; Lammertyn E; Landau EEC; Plant BJ; Smyth AR; van Koningsbruggen-Rietschel S; Middleton PG
    J Cyst Fibros; 2024 Mar; 23(2):187-202. PubMed ID: 38233247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy.
    Farley H; Poole S; Chapman S; Flight W
    Postgrad Med J; 2022 May; 98(1159):341-345. PubMed ID: 33452147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease.
    Shteinberg M; Taylor-Cousar JL
    Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32198216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evidence-based treatment of cystic fibrosis].
    Ringshausen FC; Hellmuth T; Dittrich AM
    Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis.
    Castellani C; Simmonds NJ; Barben J; Addy C; Bevan A; Burgel PR; Drevinek P; Gartner S; Gramegna A; Lammertyn E; Landau EEC; Middleton PG; Plant BJ; Smyth AR; van Koningsbruggen-Rietschel S; Girodon E; Kashirskaya N; Munck A; Nährlich L; Raraigh K; Sermet-Gaudelus I; Sommerburg O; Southern KW
    J Cyst Fibros; 2023 Nov; 22(6):963-968. PubMed ID: 37775442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.
    Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P
    Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

  • 20. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
    Lee TW; Southern KW; Perry LA; Penny-Dimri JC; Aslam AA
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005599. PubMed ID: 27314455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.